Search
Research
Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort studyTo determine the contribution of RSV to the subsequent development of severe asthma in different subgroups of children at risk of severe RSV disease.
Research
Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancyWe therefore speculate that removal of wP from the vaccine schedule contributed to the observed rise in IgE-mediated food allergy among Australian infants
Research
Assessing the effect of meningitis prevention and treatment.In high-income countries serious bacterial infections such as meningitis are uncommon, but their severity has led to prompt adoption of vaccines for...
Research
Parental Tdap boosters and infant pertussis: a case-control studyCase households had fewer immunized mothers (22% vs 32%) or fathers (20% vs 31%) but were more likely to include additional and older children. After...
Research
PIFA - Pertussis and Food allergy, a case-cohort study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergyPat Peter Tom Holt Richmond Snelling PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher
Research
The Effect of SMS Reminders on Vaccine Hesitancy in New ParentsTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Research
Infection and VaccinesListed are The Kids Research Institute Australia research teams involved in our Infection and Vaccines Program. This program sits under the Early Environment research theme.
Research
Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation studyCommunity perception of vaccine safety influences vaccine uptake. Our objective was to assess current vaccine safety monitoring by examining factors that may influence the availability of post-vaccination survey data, and thereby the specificity and sensitivity of existing signal detection methods.
Research
Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch ProtocolStaphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.
Research
Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in AustraliaAustralia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023.